Our company, LeanBio S.L. entered the Horizon 2020 program some months ago under the specific Smart-4-Fabry program. We successfully reviewed a meeting in Bilbao, as well as the mid-term meeting in Brussels with the work we developed.
Andreu Soldevila, CEO of LeanBio S.L., went to Graz (Austria) in representation of all the company and he gave a conference explaining the initial results that have been obtained these months into our laboratory. Smart-4-Fabry program will design a technology able to obtain a new nanoformulation of GLA to treat Fabry’s disease. The main objectives of these activities are reducing Frabry’s disease treatment cost and increasing life-quality of patients. The huge progress of the results were commented among all the attendants in benefit of finding a cure for a rare disease. Therefore, Smart-4-Fabry will impact on a major health problem, in compliance with societal challenges shown in H2020 Work Programmes.